Share chart Biomea Fusion, Inc.
Extended chart
Simple chart
About Biomea Fusion, Inc.
Biomea Fusion, Inc., биофармацевтическая компания, занимается открытием, разработкой и коммерциализацией необратимых малых молекул для лечения пациентов с генетически определенными видами рака. Его ведущим продуктом-кандидатом является BMF-219, перорально биодоступный, мощный и селективный необратимый ингибитор MENIN, регулятора транскрипции в онкогенной передаче сигналов при множественных раковых заболеваниях. Компания была основана в 2017 году и имеет штаб-квартиру в Редвуд-Сити, штат Калифорния.| IPO date | 2021-04-16 |
|---|---|
| ISIN | US09077A1060 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://biomeafusion.com |
| Цена ао | 2.66 |
| Change price per day: | 0% (2.66) |
|---|---|
| Change price per week: | -1.85% (2.71) |
| Change price per month: | -23.56% (3.48) |
| Change price per 3 month: | -52.84% (5.64) |
| Change price per half year: | -66.67% (7.98) |
| Change price per year: | -85.1% (17.85) |
| Change price per 3 year: | -48.05% (5.12) |
| Change price per 5 year: | 0% (2.66) |
| Change price per 10 year: | 0% (2.66) |
| Change price per year to date: | -33.67% (4.01) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Aisling Capital Management LP | 799 | 2.22 |
| FMR, LLC | 5 | 14.9 |
| State Street Corporation | 4 | 12.48 |
| Cormorant Asset Management, LP | 4 | 9.93 |
| Laurion Capital Management, LP | 3 | 7.57 |
| Baker Brothers Advisors, LLC | 2 | 5.87 |
| Blackrock Inc. | 2 | 5.49 |
| Vanguard Group Inc | 1 | 3.8 |
| Janus Henderson Group PLC | 1 | 3.58 |
| Driehaus Capital Management, LLC | 1 | 3.32 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Range Cancer Therapeutics ETF | 0.70526 | 47.24 | 0.11955 |
| iShares Micro-Cap ETF | 0.06056 | 17.09 | 1.54048 |
| Invesco Nasdaq Biotechnology ETF | 0.03027 | 28.58 | 0.8565 |
| Principal Healthcare Innovators ETF | 0.03021 | 618.5 | 0.8416 |
| Future Tech ETF | 0.03021 | 426.34 | 0.8416 |
| ProShares Ultra Nasdaq Biotechnology | 0.02071 | 51.7 | 0.85651 |
| Vanguard Russell 2000 Growth ETF | 0.02 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.0179 | 38.04 | 0.6026 |
| Vanguard Russell 2000 ETF | 0.01 | 17.16 | 1.48801 |
ProShares UltraPro Russell2000
|
0.00516 | 89.82 | 1.47873 |
Schwab U.S. Small-Cap ETF
|
0.00508 | 17.47 | 1.51433 |
| ProShares Hedge Replication ETF | 0.00147 | 5.92 | 1.47892 |
Schwab U.S. Broad Market ETF
|
0.00036 | 24.86 | 1.43354 |
| iShares Russell 3000 ETF | 0.00031 | 24.83 | 1.43482 |
| Dimensional US Core Equity Market ETF | 0.00019 | 30.98 | 1.40618 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.06 | 93.34 | 1.12 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 921.14k | 1981 (44 years) |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | 659.53k | 1963 (62 years) |
| Mr. Franco Valle | CFO & Principal Accounting Officer | 651.77k | 1981 (44 years) |
| Mr. Heow Tan | Chief Technology & Quality Officer | N/A | 1959 (66 years) |
| Ms. Naomi Cretcher | Chief People Officer | N/A | |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | N/A | 1970 (55 years) |
| Dr. Stephan Morris M.D. | Chief Development Officer | N/A | |
| Mr. Ravi Upasani | Executive Vice President of Intellectual Property | N/A | |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer | N/A | |
| Caroline Perez- Dupont | Senior Vice President of Contracts |
Address: United States, Redwood City. CA, 900 Middlefield Road - open in Google maps, open in Yandex maps
Website: https://biomeafusion.com
Website: https://biomeafusion.com
